CEO Gregory Russotti was paid $912,320 in fiscal year 2025, ↓ down 38.7% from fiscal year 2024 (SEC filing 0001104659-26-049489 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,167,015 Chad Cowan total, FY2025 Chief Scientific Officer — highest-paid officer; CEO Gregory Russotti: $912,320 | — CEO (Gregory Russotti) pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
You have just read Century Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper IPSC reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
IPSC's next annual pay disclosure, estimated May 2, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chad Cowan | $559,532 | $0 | $398,329 | $8,327 | $201,007 | $0 | $0 | $1,167,015 |
| Chief Scientific Officer | ||||||||
| Adrienne Farid | 333,348 | 0 | 71,120 | 51,240 | 0 | 0 | 533,515 | 989,403 |
| Former Chief Development Officer | ||||||||
| Gregory Russotti | 559,650 | 0 | 71,120 | 51,240 | 226,658 | 0 | 3,652 | 912,320 |
| Chief Technology and Manufacturing Officer and former Interim President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chad Cowan | $1,167,015 | — | — | — |
| Adrienne Farid | 989,403 | 1,417,304 | 1,709,916 | ↓ −427,901 |
| Gregory Russotti | 912,320 | 1,487,604 | 2,589,630 | ↓ −575,284 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
Each company listed discloses IPSC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IPSC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Adrienne Farid | Chief Development Officer | $989,403 |
| Gregory Russotti | CEO | $912,320 |
| Chad Cowan | Chief Scientific Officer | $1,167,015 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Gregory Russotti | Option | 82,131 | 5.32 | — |
| Adrienne Farid | Option | 91,872 | 13.15 | — |
| Adrienne Farid | Option | 48,664 | 5.32 | — |
| Chad Cowan | RSU | 762,543 | — | 758,730 |
| Adrienne Farid | Option | 15,462 | 1.75 | — |
| Chad Cowan | Option | 316,096 | 1.65 | — |
| Gregory Russotti | RSU | 120,000 | — | 119,400 |
| Chad Cowan | RSU | 55,782 | — | 55,503 |
| Gregory Russotti | Option | 106,256 | 2.91 | — |
| Chad Cowan | RSU | 19,500 | — | 19,402 |
| Gregory Russotti | RSU | 13,500 | — | 13,433 |
| Gregory Russotti | Option | 2,188 | 13.15 | — |
| Gregory Russotti | Option | 120,000 | 0.6 | — |
| Gregory Russotti | Option | 51,044 | 4.64 | — |
| Adrienne Farid | Option | 168,655 | 1.03 | — |
| Adrienne Farid | Option | 207,649 | 7.27 | — |
| Adrienne Farid | Option | 79,390 | 4.64 | — |
| Chad Cowan | Option | 19,500 | 0.6 | — |
The compensation of our NEOs generally consists of base salary, annual cash incentive opportunities, long-term incentive compensation in the form of equity awards, and other benefits. Equity-based incentive awards are designed to align the interests of our stockholders with those of our NEOs.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Century Therapeutics | 2025 | Gregory Russotti | $559,650 | $71,120 | $51,240 | $226,658 | $912,320 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Chad Cowan | DEF 14A | 2026-04-27 | 0001104659-26-049489 | Section “SUMMARY COMPENSATION TABLE”. As printed: 1,167,015. View filing ↗ |
| 2 | Section 01, Adrienne Farid | DEF 14A | 2026-04-27 | 0001104659-26-049489 | Section “SUMMARY COMPENSATION TABLE”. As printed: 989,403. View filing ↗ |
| 3 | Section 01, Gregory Russotti | DEF 14A | 2026-04-27 | 0001104659-26-049489 | Section “SUMMARY COMPENSATION TABLE”. As printed: 912,320. View filing ↗ |
| 4 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer. |
| 5 | Century Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001104659-26-049489 | CEO total compensation as printed in Century Therapeutics's own proxy. As printed: 912,320. View filing ↗ |